Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous exposure Nausea - a common barrier to treatment adherence with smoking cessation therapies - was reported in only 2.